CA2710964A1 - Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices - Google Patents

Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices Download PDF

Info

Publication number
CA2710964A1
CA2710964A1 CA2710964A CA2710964A CA2710964A1 CA 2710964 A1 CA2710964 A1 CA 2710964A1 CA 2710964 A CA2710964 A CA 2710964A CA 2710964 A CA2710964 A CA 2710964A CA 2710964 A1 CA2710964 A1 CA 2710964A1
Authority
CA
Canada
Prior art keywords
peptide
helix
virus
amino acid
carbon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2710964A
Other languages
English (en)
French (fr)
Inventor
Deyun Wang
Paramjit S. Arora
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2710964A1 publication Critical patent/CA2710964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2710964A 2007-12-31 2008-12-31 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices Abandoned CA2710964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1811807P 2007-12-31 2007-12-31
US61/018,118 2007-12-31
PCT/US2008/088667 WO2009110952A2 (en) 2007-12-31 2008-12-31 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices

Publications (1)

Publication Number Publication Date
CA2710964A1 true CA2710964A1 (en) 2009-09-11

Family

ID=41056505

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2710964A Abandoned CA2710964A1 (en) 2007-12-31 2008-12-31 Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices

Country Status (5)

Country Link
US (1) US8871899B2 (enExample)
EP (1) EP2247298B1 (enExample)
JP (1) JP5653219B2 (enExample)
CA (1) CA2710964A1 (enExample)
WO (1) WO2009110952A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010510236A (ja) * 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法
CA2686827C (en) 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US8613956B2 (en) * 2008-06-23 2013-12-24 International Flora Technologies, Ltd. Cosmetic particles that transform from hard to soft particles comprising hydrogenated long-chain triglyceride oils
US8524653B2 (en) 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010060112A1 (en) 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
EP2376100B1 (en) 2009-01-14 2017-10-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2774973A1 (en) 2009-09-22 2011-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
WO2013059530A2 (en) * 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014113792A1 (en) 2013-01-19 2014-07-24 New York University Hydrogen-bond surrogate peptides and peptidomimetics for p53 reactivation
EP3041492A4 (en) * 2013-09-03 2017-08-02 New York University INHIBITING INTERACTION BETWEEN HIF-1alfa AND P300/CBP WITH HYDROGEN BOND SURROGATE-BASED HELICES
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
CN108822190B (zh) * 2018-05-23 2021-11-09 中国人民解放军军事科学院军事医学研究院 多肽及其药物组合物和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5446128A (en) * 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5840833A (en) * 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
US6818740B1 (en) * 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6841657B2 (en) * 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6596497B1 (en) * 1999-03-17 2003-07-22 New York Blood Center, Inc. Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
EP1680443B9 (en) * 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
WO2005118620A2 (en) * 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
EP1755667B1 (en) * 2004-06-01 2013-07-17 Merck Sharp & Dohme Corp. Stable peptide mimetic of hiv gp41 fusion intermediate
US7981998B2 (en) * 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2686827C (en) * 2006-12-14 2014-09-16 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN109627287A (zh) * 2007-02-23 2019-04-16 爱勒让治疗公司 三唑大环系统
EP2508531B1 (en) * 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
JP5788178B2 (ja) 2008-01-23 2015-09-30 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド ウィルス感染症の治療のための組成物及び方法
US8524653B2 (en) * 2008-09-22 2013-09-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010060112A1 (en) * 2008-11-24 2010-05-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with improved properties
BR112012008831A2 (pt) * 2009-10-14 2019-09-24 Aileron Therapeutics Inc macrociclos de peptideomiméticos aprimorados.

Also Published As

Publication number Publication date
JP5653219B2 (ja) 2015-01-14
US8871899B2 (en) 2014-10-28
EP2247298B1 (en) 2016-08-31
US20110046043A1 (en) 2011-02-24
JP2011507972A (ja) 2011-03-10
EP2247298A4 (en) 2012-06-06
WO2009110952A3 (en) 2010-03-04
EP2247298A2 (en) 2010-11-10
WO2009110952A2 (en) 2009-09-11

Similar Documents

Publication Publication Date Title
US8871899B2 (en) Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
Wang et al. Discovery of hydrocarbon-stapled short α-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors
JP4682251B2 (ja) 改善された生物学的特性を有するｈｉｖ融合阻害剤ペプチド
US20080269462A1 (en) Peptide inhibitors of HIV entry
US20080241156A1 (en) Inhibitors of hepatitis C virus
US11680086B2 (en) Lipopeptide for potently inhibiting HIV, derivative thereof, pharmaceutical composition thereof and use thereof
Gallo et al. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors
WO2013150532A1 (en) Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides
CA2423004C (en) Peptide inhibitors of hiv entry
AU2001292944A1 (en) Peptide inhibitors of HIV entry
US20030219451A1 (en) Stable helical C peptides and uses therefor
Huarte et al. Membrane-transferring regions of gp41 as targets for HIV-1 fusion inhibition and viral neutralization
Xue Development of Antiviral Peptidomimetics
HK40118032B (en) Polypeptides capable of inhibiting mers-like coronavirus infections and their applications
HK40118032A (en) Polypeptides capable of inhibiting mers-like coronavirus infections and their applications
Steger III Kinetic restriction of HIV-1 entry inhibition

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20141231